Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 6,659

Document Document Title
WO/2013/012049A1
Provided are a medicinal agent and a food product, both of which prevent heart diseases such as cardiomegaly and heart failure. Specifically provided is an agent for preventing a heart disease such selected from among heart failure, card...  
WO/2013/008928A1
The purpose of the present invention is to provide a novel compound useful for the prevention or treatment of diseases such as cancerous angiogenesis, chronic rheumatoid arthritis, intimal hyperplasia, vascular atherosclerosis, hemorrhag...  
WO/2013/004116A1
The present invention relates to a compound as represented by general formula (I) and a pharmaceutically acceptable salt thereof, wherein R1 is H, hydroxyl or methoxyl; R2 is hydroxyl; R3 is heteroatom-substituted or unsubstituted organi...  
WO/2012/176804A1
The present invention addresses the problem of providing a compound having human SGLT2 inhibitory activity, a prodrug of the compound, a pharmacologically acceptable salt of the compound, and a pharmaceutical use of the compound. The pre...  
WO/2012/147102A4
The present invention relates to bioactive fractions and compounds from Dalbergia sissoo for the prevention or treatment of osteo-health related disorders. The present invention relates in the field of pharmaceutical composition that pro...  
WO/2012/117357A3
The inventions discloses a process for preparation of compounds of Formula (IX), Wherein, R is C1 -C6 alkyl, R1 is hydrogen or a hydroxyl protecting group, and R2 is hydrogen or fluorine.  
WO/2012/139134A3
Described herein, at least in part, are methods of modulating oncogenic fusion proteins.  
WO/2012/166705A2
Described herein are hydrogelators that include a nucleobase, an amino acid, and a glycoside. The hydrogelators have increased resistance to proteases and can self-assemble into supramolecular nanofibers or hydrogels. The supramolecular ...  
WO/2012/162412A2
The present invention includes compositions comprising a synergistic fungicidal combination of a polyene fungicide and at least, one lipopeptide and methods for using such compositions in controlling fungal pathogens.  
WO/2012/156897A1
A method for generating human milk oligosaccharides (HMOs) or precursors thereof, compounds obtainable by the method and uses and compositions involving such compounds. The method comprising the steps of a) Providing at least one donor s...  
WO/2012/085784A3
The present invention relates to polyene macrolide derivatives according to the formula (I): wherein M is a macrocyclic lactone ring; N is a polyene sugar, substituted or unsubstituted; X is independently selected from O, S, N or NH; R i...  
WO/2012/116196A3
The invention provides methods for producing compounds comprising a substitution at the 1'-position of a lactosyl ring. Also provided are compounds having a radionuclide, such as 18F substituted at the 1'-position of a lactosyl ring. Com...  
WO/2012/147102A1
The present invention relates to bioactive fractions and compounds from Dalbergia sissoo for the prevention or treatment of osteo-health related disorders. The present invention relates in the field of pharmaceutical composition that pro...  
WO/2012/144080A1
The purpose of the present invention is to provide a novel TRPV receptor activator which is suitable for the improvement in a skin barrier function. The purpose can be achieved by providing a TRPV receptor activator which comprises at le...  
WO/2012/142960A1
Disclosed is an anti-infective drug―macrolide compound, preparation and uses thereof. Macrolide compound, namely erythromycin ethylsuccinate crystalline hydrate, which has less moisture absorption and good storage stability, can be use...  
WO/2012/129651A1
The invention provides compounds of formula (I) with substituents as specified in claim 1 for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceuticals compositions including the compounds or prodrugs of the com...  
WO/2012/129473A1
The present invention provides complexes of gallium with a ligand, methods of making the complexes, methods of using the complexes and pharmaceutical gallium compositions comprising the complexes, in particular those compositions suitabl...  
WO/2012/127351A1
A process for the preparation of compound of Formula (I) is provided. Formula - I  
WO/2012/127410A1
A method for the synthesis of a compound of formula (1) or a salt thereof, wherein A is a carbohydrate linker which is a lactosyl moiety or which consists of a lactosyl moiety and at least one monosaccharide unit selected from the group ...  
WO/2012/121297A1
[Problem] To provide a method for producing an ascorbic acid 2-glucoside anhydrous crystal-containing powder with which it is possible to produce a powder that will not show significant solidification, even when the percentage of ascorbi...  
WO/2012/118048A1
A novel monoalkylamino intermediate (I); and a process of producing a compound represented by formula (III), which is an antibacterial agent for animals, through the novel monoalkylamino intermediate.  
WO/2012/115256A1
A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas).  
WO/2012/116196A2
The invention provides methods for producing compounds comprising a substitution at the 1'-position of a lactosyl ring. Also provided are compounds having a radionuclide, such as 18F substituted at the 1'-position of a lactosyl ring. Com...  
WO/2012/051126A3
The invention provides novel compounds and compositions and methods for making and using the compounds and compositions.  
WO/2012/105562A1
The inventors have successfully obtained a compound having josamycin as the lead mother nucleus and having excellent antibacterial activity against the causative bacteria of respiratory tract infection in animals.  
WO/2012/105563A1
It was found compound (1) has excellent antibacterial activity against the causative bacteria of respiratory tract infection in animals.  
WO/2010/015703A3
The invention relates to novel anti-bacterial 15-membered 6-O-substituted-8a-aza-8a- homoerythromycin A and 6-O-substituted-9a-aza-9a-homoerythromycin A, their 6-O- substituted-3-O-decladinosyl-3-oxy and 6-O-substituted-3-O-decladinosyl-...  
WO/2012/076989A1
The invention relates to ketolide compounds of Formula (I) and their pharmaceutically acceptable salts, solvates, hydrates, polymorphs and stereoisomers having antimicrobial activity. The invention also provides pharmaceutical compositio...  
WO/2012/070024A1
Compositions for the treatment of cancer comprising coumarin and thiocoumarin derivatives of Formulas I- XII are disclosed. Said derivatives preferentially inhibit carbonic anhydrase IX and XII (which are associated with hypoxic and meta...  
WO/2012/065054A1
A compound, or a pharmaceutically acceptable salt, ester, hydrate or solvate thereof, comprising formula I: A-B wherein A comprises a carbohydrate that is a neuraminidase or galactosidase substrate; B comprises an odorant moiety; B is co...  
WO/2012/061984A1
The present invention discloses a method for preparing high purity paeoniflorin and albiflorin simultaneously comprising: extraction the raw material peony by percolation or heating reflux to obtain the peony extract solution, then purif...  
WO/2012/061931A1
The present invention relates to the use of a natural compound in diabetes prevention. More specifically, the invention relates to the use of geniposide as a pancreatic beta cell protectant for diabetes prevention and treatment.  
WO/2012/061477A1
The invention provides coelenterazine derivatives which are substrates for a non-luminescent enzyme and a pro-substrate for a luminescent enzyme. The invention also provides a method of using the derivatives.  
WO/2012/051126A2
The invention provides novel compounds and compositions and methods for making and using the compounds and compositions.  
WO/2012/048522A1
A new fructosylated puerarin represented by Formula (I), a preparation method therefor and a use thereof in preparation of drugs for treating cardio-cerebrovascular diseases and/or tumor related diseases. R1 and R2 in Formula (I) are eac...  
WO/2012/049521A1
There is provided a method of glycosylating an aminocoumarin compound comprising conjugating a sugar to the 4'-OH position of the core of the aminocoumarin compound. Also provided is an aminocoumarin compound glycosylated at the 4'-OH po...  
WO/2012/047763A2
Flavonoid glycosides, such as isoquercitrin, are shown to stimulate the formation of neuritis and neuronal synapses in neurons and neuronal progenitor (stem) cells.  
WO/2012/038614A1
The present invention relates to sulfonated coumarins, to the synthesis thereof, to fluorogenic substrates resulting from grafting said coumarins onto sugars, to a method for preparing said substrates, and to the uses thereof. The substi...  
WO/2012/038372A1
The present invention concerns a process for the preparation of the compound of formula (1). The compound of formula (1) is the key intermediate in the synthesis of some antibacterial agents of the triamilide class, such as Tulathromycin...  
WO/2012/033218A1
The objective of the present invention is to provide novel 2-O-α-D-glucosyl-L-ascorbic acid crystals, a method for producing the novel 2-O-α-D-glucosyl-L-ascorbic acid crystals, and use of the novel 2-O-α-D-glucosyl-L-ascorbic acid cr...  
WO/2011/150775A1
Disclosed is a method for treating a fermentation liquor of natamycin which is a fungus inhibitor. In this method, protease and lipase are added to the fermentation liquor for enzymolysis. Water insoluble proteins and lipid in filter cak...  
WO/2011/147316A1
Disclosed are levocarrimycin, pharmaceutical compositions, preparation methods and uses thereof. Levocarrimycin is a mixture of isovalerylspiramycin III, II and I as main components and contains certain content of isobutyrylspiramycin II...  
WO/2011/147313A1
Disclosed are levoisovalerylspiramycin I, II or III, preparations, preparation methods and uses thereof. The preparations comprise levoisovalerylspiramycin I, II or III and pharmaceutically acceptable carrier and/or adjuvant, wherein the...  
WO/2011/137758A1
Provided are ketolide derivatives of general formula (I) or (II), or pharmaceutically acceptable salts or esters thereof formed with inorganic acids or organic acids. In the formula, Ar represents aromatic heterocyclic alkyl or substitut...  
WO/2011/131749A1
(E)-11,12-Didehydro-11,12-dideoxy 14-membered macrolides and 15-membered azalide macrolides represented by Formula (I): useful in the treatment of neutrophil dominated inflammatory diseases, especially in the treatment of neutrophil domi...  
WO/2011/127948A1
Analogues of etoposide for the treatment of patients having a tumour, more particularly a tumour that is metastatic and/or that reduces an organ function, are provided. The invention also relates to an in vitro method of selecting a resp...  
WO/2011/128869A1
This invention relates to a macrolide composition, more particularly an amorphous form (Form-III) of 3R, 4S, 5S, 6R, 7R, 9R, 11S, 12R, 13S, 14R-6- [(2S, 3R, 4S, 6R)-4-dimethylamino-3- hydroxy-6-methyloxan-2-yl]oxy-14- ethyl-7, 12, 13-tri...  
WO/2011/128115A1
Analogues of etoposide for the treatment of patients having a tumour, more particularly a tumour that is metastatic and/or that reduces an organ function, are provided. The invention also relates to an in vitro method of selecting a resp...  
WO/2011/119604A1
New crystalline forms of macrolide compounds, and pharmaceutical compositions thereof, are described herein. In addition, processes for preparing the crystalline forms are described herein.  
WO/2011/119549A1
The present invention relates to trioxacarcin compounds of the formula: (I) or pharmaceutically acceptable forms thereof; wherein R1, R2, R3, R4, R5, R6, R7, R8, and R9 are as defined herein. The present invention also provides processes...  

Matches 301 - 350 out of 6,659